FDA approves Amgen's biosimilar to J & J's rheumatoid arthritis drug
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson&Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.
ConclusionsOur results suggest that, in practice, half of patients with RA and two thirds with PsA or AS maintained the first biological, but with frequent dose adjustments.ResumenObjetivoDescribir el manejo terapéutico de la artritis reumatoide (AR), la artritis psoriásica (Aps) y la espondilitis anquilosante (EA) en pacientes que inician tratamiento con agentes biológicos.Materiales y métodosEstudio observacional, retrospectivo, longitudinal en 33 hospitales españoles. Se incluyeron pacientes con AR, Aps y EA que iniciaron tratamiento con agentes biológicos entre septiembre de 20...
Publication date: Available online 25 January 2020Source: Best Practice &Research Clinical RheumatologyAuthor(s): Teresa Otón, Loreto CarmonaAbstractNo published epidemiological study has specifically focused on the prevalence of established rheumatoid arthritis (RA), as epidemiologists do not study established RA separated from RA as a whole; especially no incidence studies can be found, as incidence refers to new cases (early RA). Such a study, if it existed, would find a prevalence much larger than that of recent-onset RA, and should be planned based on clear definitions that currently do not exist in epidemi...
Publication date: Available online 25 January 2020Source: Best Practice &Research Clinical RheumatologyAuthor(s): Ayşe A. KüçükdeveciAbstractThe goals in the management of established rheumatoid arthritis (RA) are to control pain and disease activity, prevent further joint damage, and enhance functioning and quality of life. Despite the fact that aggressive and the early use of biological and nonbiological disease-modifying antirheumatic drugs have been associated with substantial gains in clinical, radiological, and disability outcomes, a considerable proportion of patients still report significant p...
ConclusionThe present study clarifies the mechanism of P. sinensis against GA, and provides evidence to support its clinical use.Graphical abstract
ConclusionTo our knowledge, this is the first report of the metabolite profiling of the G. elegans crude extract in goats, which is of great significance for a safer and more rational application of this herbal medicine.Graphical abstract
Conclusions: CU modeling for RA increasingly reflects real-world conditions and patient experiences which are anticipated to provide better information in the assessment of health technologies. Future CU models in RA should consider applying the observed advances in modeling choices to optimize their CU predictions and simulation of real-world outcomes. PMID: 31971039 [PubMed - as supplied by publisher]
No abstract available
CONCLUSIONS: The influence of traditional cardiovascular risk factors on cIMT and carotid plaque is similar in RA and SLE. PMID: 31969232 [PubMed - as supplied by publisher]
CONCLUSIONS: ABT treatment significantly affected IFN-γ and CXCL10 cytokine levels in vitro. In addition, serum CXCL10 levels were associated with better responses in ABT treatment. PMID: 31969227 [PubMed - as supplied by publisher]
CONCLUSIONS: In RA patients treated with TCZ in perfusion, the rate of surgical complications was low: 8.6%. The median time between surgery and last infusion was relatively short according to half-life of TCZ but did not influence the rate of postoperative complications. PMID: 31969215 [PubMed - as supplied by publisher]